Drug
Admilparant clinical trials
Also written BMS-986278.
- studies test it
- 18
- open now
- 1
- in phase 3
- 3
- first study started
- 2018
Keep track of what changes. Save the admilparant studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
Development codes
Studies by the year they started
18 studies that test it; most in 2023 (5)
| Year | Studies |
|---|---|
| 2018 | 2 |
| 2019 | 1 |
| 2020 | 2 |
| 2023 | 5 |
| 2024 | 4 |
| 2025 | 2 |
| 2026 | 2 |
By phase
A phase 1/2 study counts in both.
- Phase 1
- 14
- Phase 2
- 1
- Phase 3
- 3
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 18 · Other 0
Often tested with
Tested in the same studies.
Moxifloxacin (2) · Nintedanib (1) · Sildenafil (1) · Esomeprazole (1) · Pirfenidone (1) · Rifampin (1)
Studies
Open first, then newest update. How each study uses admilparant is read from its arms, and is right about nine times in ten.
Testing it · 18
- Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With Pulmonary FibrosisNot yet recruitingPhase 3Bristol-Myers SquibbNCT07441408Written as BMS-986278
- A Study to Evaluate the Effect of BMS-986278 on Cardiac Repolarization in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT07422298Written as BMS-986278
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Progressive Pulmonary FibrosisActive, not recruitingPhase 3Bristol-Myers SquibbNCT06025578Written as BMS-986278
- A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants With Idiopathic Pulmonary FibrosisActive, not recruitingPhase 3Bristol-Myers SquibbNCT06003426Written as BMS-986278
- A Study Measuring the Effectiveness, Safety, and Tolerability of BMS-986278 in Participants With Lung FibrosisCompletedPhase 2Bristol-Myers SquibbNCT04308681Written as BMS-986278
- A Study to Assess the Effect of Food on the Drug Levels of AdmilparantCompletedPhase 1Bristol-Myers SquibbNCT07225647Written as Admilparant
- A Study to Evaluate BMS-986278 in Participants With Normal Renal Function, Severe Renal Impairment, or End-Stage Renal Disease on Intermittent HemodialysisCompletedPhase 1Bristol-Myers SquibbNCT06723535Written as BMS-986278
- A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of BMS-986278 and the Effects of BMS-986278 on Cardiac Repolarization in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT06746402Written as BMS-986278
- A Study to Evaluate Comparative Bioavailability of BMS-986278 in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT06715683Written as BMS-986278 Batched method, Dose A
- A Study to Assess the Extent of Drug Interaction Between BMS-986278 and Nintedanib, the Relative Bioavailability of BMS-986278 in Tablet and the Effect That Food Has on BMS-986278 in Tablet Formulations in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT06568458Written as BMS 986278
- Study to Assess Drug Levels and Safety of BMS-986278 in Healthy Participants and Participants With Different Degrees of Hepatic ImpairmentCompletedPhase 1Bristol-Myers SquibbNCT06425198Written as BMS-986278
- A Study to Investigate the Effects of BMS-986278 on Drospirenone and Ethinyl Estradiol Drug Levels in Healthy Female ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05985590Written as BMS-986278
- A Study to Evaluate the Drug Levels, Safety, and Tolerability of BMS-986278 in Healthy Chinese ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05805904Written as BMS-986278
- A Study Investigating the Safety, Tolerability, Drug Levels and Drug Effect of BMS-986278 in Healthy Adult Participants (Part 1) and Japanese Participants (Part 2)CompletedPhase 1Bristol-Myers SquibbNCT05684289Written as BMS-986278
- A Study to Assess the Levels in Blood Plasma of BMS-986278 in Healthy Participants Following Administration of Tablets, With or Without Food, and in the Presence of an Antacid (Esomeprazole)CompletedPhase 1Bristol-Myers SquibbNCT04468815Written as BMS-986278 Tablet
- A Study of the Pharmacokinetic Interaction Between Pirfenidone and BMS-986278 in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03981094Written as BMS-986278
- A Study of Experimental Medication BMS-986278 Given to Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03429933Written as BMS-986278
- An Investigational Study of Experimental Medication BMS-986278 Given With the Antibiotic Rifampin in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03712540Written as BMS-986278
Given in every arm · 2 — admilparant is usual care beside what is tested
- A Study to Assess the Effect of Multiple Doses of Itraconazole, Gemfibrozil, or Carbamazepine on BMS-986278 in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05932303Written as BMS-986278
- Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986278 in Healthy Male ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT04567667Written as [14C] BMS-986278
Codes
What other systems call admilparant · ClinicalTrials.gg INT014935
- UNII (FDA) 4UN9AOU6G8ADMILPARANTOne source FDA
- NCI Thesaurus C203025AdmilparantOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 4UN9AOU6G8 | ADMILPARANT | One source FDA |
| NCI Thesaurus | C203025 | Admilparant | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.